Device Trial Radar · NCT06904365
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Apr 8, 2025
Primary completion
Oct 14, 2026
Study completion Oct 14, 2026
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Varian Medical Systems
- First posted
- Apr 1, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- Female only, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Female patients with early onset (\<50 years old) pelvic malignancies such as uterine and rectal cancers are rising in incidence, which often requires pelvic radiation; many of these patients are premenopausal and at a high risk of premature ovarian failure from radiotherapy. Premature ovarian failure carries significant cardiac, musculoskeletal, sexual, and psychosocial morbidity. Ovarian transposition carries variable success rates, is not readily accessible to the general population, and can still be at risk of clinically significant radiotherapy doses. There is an unmet need for innovative techniques to protect ovarian function.
Conditions
- Uterine Cancer
- Rectal Cancer
- Colon Cancer
- Breast Cancer
- Lung Cancer
- Sarcoma
- Cervix Cancer
- Head and Neck Cancer
- Anal Cancer
- Liver Cancer
- Gastric Cancer
- Bladder Cancer
Interventions
HyperSight cone beam computed tomography (CBCT) scanDevice
HyperSight is a novel onboard imaging platform with a rapid-acquisition high-quality CBCT imager capable of acquiring images sufficient for simulation and treatment.
ETHOS 2.0Device
ETHOS 2.0, an artificial intelligence treatment planning system, will be utilized in an emulator to create SCRT plans to determine the feasibility of clinically significant ovarian dose reductions in-silico.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of ovarian visualizationTime frame: Estimated to be 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.